Converting Cold into Hot Tumors by Combining Immunotherapies

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Metastatic melanoma remains a significant challenge in cancer treatment.
• Current immunotherapies like anti-PD-1 have limitations in efficacy for some patients.

Purpose of the Study:

• To evaluate the safety and efficacy of combining oncolytic virus therapy with anti-PD-1 in metastatic melanoma.
• To assess the impact of this combination on tumor immune microenvironment.

Main Methods:

• Phase Ib clinical study.
• Intralesional injection of a modified human herpes simplex virus.
• Systemic administration of anti-PD-1 therapy.

Main Results:

• A 62% objective response rate was observed in patients treated with the combination therapy.
• Enhanced T cell infiltration was noted within virus-injected lesions.
• The combination was generally well-tolerated.

Conclusions:

• Combination of oncolytic virus and anti-PD-1 demonstrates promising efficacy in metastatic melanoma.
• Oncolytic virus therapy may enhance the anti-tumor immune response when combined with checkpoint inhibitors.
• Further investigation in larger trials is warranted.